Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives $34.75 Average Price Target from Brokerages

Smith & Nephew SNATS, Inc. (NYSE:SNN) has been assigned an average recommendation of “Hold” from the five brokerages that are presently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $34.75.

Several analysts have weighed in on the company. Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, March 29th. Canaccord Genuity Group set a $32.00 price objective on Smith & Nephew SNATS in a research report on Friday, April 24th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Monday, April 20th.

Smith & Nephew SNATS Price Performance

Smith & Nephew SNATS stock opened at $31.19 on Friday. The stock’s 50 day simple moving average is $33.38 and its two-hundred day simple moving average is $33.78. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a fifty-two week low of $27.97 and a fifty-two week high of $38.79.

Smith & Nephew SNATS (NYSE:SNN) last posted its quarterly earnings data on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share for the quarter. The firm had revenue of $1.60 billion for the quarter. As a group, equities analysts forecast that Smith & Nephew SNATS will post 2.29 earnings per share for the current year.

Smith & Nephew SNATS Announces Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be given a dividend of $0.482 per share. This represents a yield of 304.0%. The ex-dividend date of this dividend is Friday, March 27th.

Institutional Trading of Smith & Nephew SNATS

Several large investors have recently bought and sold shares of the company. Garner Asset Management Corp purchased a new stake in shares of Smith & Nephew SNATS in the 4th quarter worth approximately $27,000. Arax Advisory Partners grew its stake in shares of Smith & Nephew SNATS by 142.6% in the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 569 shares during the last quarter. Advisors Asset Management Inc. purchased a new stake in shares of Smith & Nephew SNATS in the 4th quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Smith & Nephew SNATS in the 3rd quarter worth approximately $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Smith & Nephew SNATS in the 4th quarter worth approximately $43,000. 25.64% of the stock is owned by institutional investors.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.